Nippon Medical Research, Inc.

Address:	Kita Aoyama 1-5-12/3F, Minato-ku, Tokyo 107-0061, Japan
Phone:	813-5414-2614
Facsimile:	813-5414-2768
CEO:	Mr.Gensuke T. TOKORO, Chief Executive Officer
Capital:	JPY 426 Million (as of the end of March 2003)
E-mail:	NMEDICALR@aol.com ; info@nmr.jp
Website:	http://www.nmr.jp/

General Company Profile:

The Japanese bio-medical venture company, Nippon Medical Research, Inc. ("NMR"), is developing an injectable antibiotic which has demonstrated an excellent bactericidal efficacy and safety features in animal studies as a first-line therapy against MRSA^1),3) infections. The compound, WAP-8294A2²⁾, is now being further developed by NMR as an alternative to vancomycin, having a narrow spectrum of activty and being effective in a once-daily regimen.

NOTES:
1) What is MRSA?
* methicillin-resistant Staphylococcus aureus
- Nosocomial & Community acquired infection
- Nosocomial blood infection (Septicemia & Bacteremia)
- Surgical wounded infections (Septicemia & Bacteremia) (Catheter surgery)

2) What is WAP-8294A₂?
* A New Anti-MRSA Depsipeptide Group
Antibiotic produced by Lysobactor sp. A main component (77%) in a complex of water-soluble depsipeptide group antibiotic produced by a Gram-negative bacterium Lysobacter sp. showed higher than vancomycin in vivo activity against MRSA.

3) The Emergence of VRSA, June 2002
Michigan, United States (confirmed by CDC MMWR Report of July 5, 2002)
VRSA * vancomycin-resistant Staphylococcus aureus

Nippon Medical Research, Inc. Address: Kita Aoyama 1-5-12/5F, Minato-ku,Tokyo 107-0061, Japan Phone: 813-5414-2614 Facsimile: 813-5414-2768 [PR]レーシック